ArticleFrontiers in genetics2019
DNA Data Marketplace: An Analysis of the Ethical Concerns Regarding the Participation of the Individuals.
Article in Frontiers in genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- When genomics companies act as biobanks: governance challenges in an era of genomic assetization.Frontiers in genetics · 2026Article
- "ItResearch ethics · 2025Article
- Blockchain Technology in Digital Health and Medical Technologies.Blockchain in healthcare today · 2025Article
- Ethical considerations for biobanking and use of genomics data in Africa: a narrative review.BMC medical ethics · 2023Review
- The Pitfalls of Genomic Data Diversity.The Hastings Center report · 2023Article
- Ethics of Buying DNA.Journal of bioethical inquiry · 2022Article
- A scoping review of distributed ledger technology in genomics: thematic analysis and directions for future research.Journal of the American Medical Informatics Association : JAMIA · 2022Article
- Blockchains as a means to promote privacy protecting, access availing, incentive increasing, ELSI lessening DNA databases.Frontiers in digital health · 2022Review
- "Idealists and capitalists": ownership attitudes and preferences in genomic citizen science.New genetics and society · 2022Article
- Health Datasets as Assets: Blockchain-Based Valuation and Transaction Methods.Blockchain in healthcare today · 2022Review
- The Data Governance Act and the EU's move towards facilitating data sharing.Molecular systems biology · 2021Article
- Article
- A survey of direct-to-consumer genotype data, and quality control tool (Computational and structural biotechnology journal · 2021Article
- Informed Consent Form Challenges for Genetic Research in Jordan.Journal of multidisciplinary healthcare · 2020Article
- Impute.me: An Open-Source, Non-profit Tool for Using Data From Direct-to-Consumer Genetic Testing to Calculate and Interpret Polygenic Risk Scores.Frontiers in genetics · 2020Article
- Genomic Sequencing Capacity, Data Retention, and Personal Access to Raw Data in Europe.Frontiers in genetics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Personal genomic data and the related health data are valuable resources for both public-funded research, and for-profit entities in development of new drugs, therapies, and diagnostic tests. In order to access to large datasets, pharmaceutical and biotech companies have developed partnerships with public and private entities such as direct-to-consumer genetic testing companies to buy genomic and health related databases collected from research participants and customers. Although individuals mainly support data sharing for research purposes, the for-profit nature of such data sharing raises some questions regarding the rights of the data subjects and fairness in sharing benefits. In response, a new generation of sequencing and data sharing startups such as Nebula Genomics, LunaDNA, and EncrypGen are emerging which aim for leaving the data control in the hands of each individual customer. In particular, such so-called "DNA data marketplaces" allow individuals to receive various types of monetary incentives to sequence their genome and share it with interested commercial parties. This paper aims to provide an exploratory and critical review of the ethical challenges related to establishing such marketplaces for genomic and health data sharing. In the view of the growing number of startups developing such marketplaces, a thorough analysis of the relevant ethical concerns is timely and needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.